Another prime example of how we put our members Ahead of the Curve. Arena Pharmaceuticals' (#ARNA) stock was trading range bound when this article was published. We suggested that a breakout to the upside to $11 - $11.50 with initial resistance at $9.90 to $10 was likely in the near future. Five days later, ARNA broke out hitting and intra-day high of $10.02 and closing at $9.99. The stock has since retreated a bit as we predicted, and is basing for another move upward. Our article explained upcoming catalysts that are likely to help propel the stock upwards in the coming weeks. Sign up today to start receiving this type of actionable analyis and Get Ahead of the Cruve.
Here's a screen shot from Google finance showing the article and ARNA's subsequent price action (click to enlarge).
This article was published by Seeking Alpha on October 12, 2012
Shares of Arena Pharmaceuticals (ARNA) have been consolidating in an ever tighter range since the June 27th approval of their obesity drug BELVIQ. Today the company issued a press release about advancing one of their pipeline drug candidates, APD811 for pulmonary arterial hypertension, into a second Phase I clinical trial which is a multiple dose, dose ranging and safety study. We believe that ARNA may be poised for a move back to the $11 range in the coming weeks due to pending catalysts as outlined herein.
